Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
6 reports, 3 independent
Updated Oct 1
Gone quiet
- Reports
- 6
- Developments
- 5
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Chardan Capital downgraded its price objective for Iovance Biotherapeutics, which trades on the Nasdaq stock exchange.Sub-event
- Iovance Biotherapeutics stock traded on Nasdaq and was compared to Nvidia's past growth.Sub-event
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.Sub-event
Iovance Biotherapeutics gained conditional approval for its lead therapy and listed as a penny stock.1 source
Iovance Biotherapeutics gained FDA approval for its therapy and is listed on Nasdaq.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
- FDA
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- FDA granted accelerated approval for VOCERYQ, causing INOVIO stock to lead Nasdaq gainers.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.